Clinical and Radiographic Success of MTA vs Biodentine

Conditions

• Indirect Pulp Cap
• Pulpotomy

Eligibility Criteria

Sex

ALL

Age

2 Years - 12 Years

Healthy Volunteers

Accepted

Interventions

• Biodentine — DEVICE
  During a patients procedure, one tooth will receive Biodentine instead of MTA.
• mineral trioxide aggregate (MTA) — BIOLOGICAL
  mineral trioxide aggregate (MTA)

Study Details

The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration like MTA. Biodentine may be an alternative medicament used for vital pulp therapy in primary molars.

Key Dates

Start date

Nov 12, 2021

Status verified

Dec 2025

Primary completion

Aug 1, 2026

Completion

Dec 1, 2026

Study Design

Enrollment

646 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: MTA, then Biodentine
  The participant will receive the standard of care procedure using MTA in on a right primary molar. A left primary molar will then be treated using Biodentine.
• Experimental: Biodentine, then MTA
  Investigators will prepare and treat a participants right primary molar with Biodentine. The participant will then receive the standard of care procedure using MTA in on a left primary molar.

Primary Outcome Measure

Rate of clinical success in pulpotomies and indirect pulp caps [ Time Frame: 4 years ]

Central Contacts

• Gayatri Malik, DMD
  570-271-6355
  [email protected]
• Samantha R Crissinger
  570-271-7499
  [email protected]

Locations (1)

Find similar trials in Danville, PA